Mr. Kim, a seasoned business and legal executive as well as serial entrepreneur, brings experience encompassing IP management, technology transfer, due diligence, business and corporate development. Prior to Vigilant Biosciences, Mr. Kim founded AerovectRx Corporation, the first spin-off company from the CDC.

Eric M. Stone possesses fifteen years of domestic and international marketing, business development, and commercial leadership experience in the health and technology sectors. Most recently with Abbott, Stone launched the market-leading drug eluting stent and the world’s first completely bioresorbable coronary stent. Previously, he served as the Principal & Founder of an organizational effectiveness and strategic marketing boutique consultancy.

Mr. Grage joins Vigilant Biosciences bringing close to thirty years in the medical products industry for developing diagnostic devices, therapeutic devices and drugs from product concepts to commercialization. Mr. Grage has gained broad experience in the business, marketing and clinical aspects of the medical products industry ranging from Roche Diagnostics, LifeScan, Amira, Cholestech, Facet, among others.

Dr. Franzmann is the principal inventor for the proprietary oral cancer biomarker technology exclusively licensed to Vigilant Biosciences from the University of Miami. Dr. Franzmann is certified by the American Board of Otolaryngology specializing in otolaryngology and plastic surgery with the head and neck otolaryngology as an Associate Professor of Otolaryngology at the University of Miami Miller School of Medicine.

Mr. Goodman brings to Vigilant broad experience in dental manufacturing and distribution including turning around the annual sales of the pioneering oral cancer screening product (ViziLite) from $300K to $16MM in 3 years. Prior engagements and roles for Mr. Goodman include having served as President of Dent-X, CEO of a leading online dental marketplace business, President of ESPE America and Director of Marketing for Benco Dental.

As an entrepreneur, a political advisor and an engineer, Jeffrey D. Marrazzo has been at the center of government-led healthcare reform efforts and on the cutting edge of medicine as a start-up executive in the fields of genomics and regenerative medicine. Most recently, Mr. Marrazzo was a part of the founding team at Generation Health, the first company in a new field of genetic benefit management, up to and following the acquisition by CVS.

A board-certified forensic pathologist who began his medical career in the U.S. Navy and later served as chief operating officer of the American Hospital Association and several biotech companies, Dr. Lord was the former chief innovation officer and senior vice president of Humana. During his time at Humana, he created Humana’s Innovation Center. Lord also serves or has served as a member of a number of prestigious boards and organizations, incl